A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
for Chronic Lymphocytic Leukemia
43 locations incl. Mobile
Sponsor: Merck Sharp & Dohme LLC
Sex: All·Age: 18+
Code: NCT06136559·Phase 3·Recruiting·Listed Nov 2023